BOSTON--(BUSINESS WIRE)--Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
“Dr. Pande is a seasoned expert in central nervous system disorders and has advanced novel neurological therapies at some of the world’s leading pharmaceutical and biotechnology companies,” said Andrew Miller, Ph.D., Karuna’s Chief Executive Officer. “Dr. Pande’s impressive background and experience will be a valuable asset as Karuna continues to explore the potential of KarXT for the treatment of CNS disorders.”
Dr. Pande has more than two decades of experience in drug development. Dr. Pande is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. Dr. Pande has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer's and Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. He currently serves as Chief Medical Officer and Scientific Advisory Board member at Tal Medical; Senior Advisor to PureTech Health; on the Board of Directors of Axovant Sciences (NYSE:AXON) and Autifony Therapeutics; on the Scientific Advisory Board of Cennerv Pharma; and as President of Verity BioConsulting. Dr. Pande began his career as a faculty member at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.
“I’m excited to join Karuna’s Board of Directors and to work with Drs. Ben Shapiro and Ed Harrigan again to address the significant unmet need in CNS disorders, including schizophrenia and Alzheimer’s disease,” said Dr. Pande. “Schizophrenia can be severely debilitating, and the millions of people impacted by the disorder continue to seek new and better treatments that can adequately and safely manage their symptoms.”
Dr. Pande joins current Board members including Ben Shapiro, M.D., former Executive Vice President of Research for Merck; Edmund Harrigan, M.D., former Senior Vice President for Worldwide Safety and Regulatory, Head of Worldwide Business Development at Pfizer; Andrew Miller, Ph.D., Co-founder and Chief Executive Officer of Karuna; Eric Elenko, Ph.D., Co-founder of Karuna and Executive Vice President of Science and Technology at PureTech Health; and Steve Muniz, Executive Vice President of Legal, Finance and Operations at PureTech Health.
About Karuna
Karuna is a clinical-stage drug development
company targeting muscarinic receptors for the treatment of central
nervous system disorders. Karuna's lead program, KarXT,
is a product candidate consisting of xanomeline,
a novel clinical-stage muscarinic acetylcholine receptor agonist
(activator) that has demonstrated efficacy in reducing psychosis and
improving cognition in placebo-controlled human trials in schizophrenia
and Alzheimer’s disease, and trospium
chloride, an FDA-approved and well-established muscarinic receptor
antagonist (blocker) that has been shown not to enter the central
nervous system. For more information, visit www.karunapharma.com.
Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events or
otherwise.
